ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by Zacks Research to Hold

Zacks Research lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday morning,Zacks.com reports.

ANIP has been the subject of several other research reports. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $107.33.

ANI Pharmaceuticals Stock Down 2.0%

Shares of NASDAQ:ANIP opened at $78.01 on Thursday. ANI Pharmaceuticals has a 1 year low of $56.71 and a 1 year high of $99.50. The business has a 50 day simple moving average of $77.29 and a two-hundred day simple moving average of $80.48. The firm has a market capitalization of $1.77 billion, a PE ratio of 19.75 and a beta of 0.46. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the previous year, the business earned $1.70 earnings per share. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts predict that ANI Pharmaceuticals will post 7.73 EPS for the current year.

Insider Buying and Selling

In related news, SVP Thomas Andrew Rowland sold 4,772 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares of the company’s stock, valued at $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 55,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the transaction, the chief executive officer directly owned 349,889 shares of the company’s stock, valued at $27,140,889.73. This trade represents a 13.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 100,564 shares of company stock valued at $7,800,862 over the last ninety days. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of ANIP. KBC Group NV bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $28,000. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $28,000. Hantz Financial Services Inc. raised its stake in ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals in the fourth quarter worth approximately $48,000. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals in the second quarter worth approximately $50,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.